The CRCbiome study: a large prospective cohort study examining the role of lifestyle and the gut microbiome in colorectal cancer screening participants.
Adenoma
Advanced neoplasia
Biomarkers
Colonoscopy
Colorectal cancer
Diet
FIT
Gut microbiome
Lifestyle
Metagenomics sequencing
Prescription drugs
Screening
iFOBT
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
18 Aug 2021
18 Aug 2021
Historique:
received:
16
12
2020
accepted:
27
07
2021
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Colorectal cancer (CRC) screening reduces CRC incidence and mortality. However, current screening methods are either hampered by invasiveness or suboptimal performance, limiting their effectiveness as primary screening methods. To aid in the development of a non-invasive screening test with improved sensitivity and specificity, we have initiated a prospective biomarker study (CRCbiome), nested within a large randomized CRC screening trial in Norway. We aim to develop a microbiome-based classification algorithm to identify advanced colorectal lesions in screening participants testing positive for an immunochemical fecal occult blood test (FIT). We will also examine interactions with host factors, diet, lifestyle and prescription drugs. The prospective nature of the study also enables the analysis of changes in the gut microbiome following the removal of precancerous lesions. The CRCbiome study recruits participants enrolled in the Bowel Cancer Screening in Norway (BCSN) study, a randomized trial initiated in 2012 comparing once-only sigmoidoscopy to repeated biennial FIT, where women and men aged 50-74 years at study entry are invited to participate. Since 2017, participants randomized to FIT screening with a positive test result have been invited to join the CRCbiome study. Self-reported diet, lifestyle and demographic data are collected prior to colonoscopy after the positive FIT-test (baseline). Screening data, including colonoscopy findings are obtained from the BCSN database. Fecal samples for gut microbiome analyses are collected both before and 2 and 12 months after colonoscopy. Samples are analyzed using metagenome sequencing, with taxonomy profiles, and gene and pathway content as primary measures. CRCbiome data will also be linked to national registries to obtain information on prescription histories and cancer relevant outcomes occurring during the 10 year follow-up period. The CRCbiome study will increase our understanding of how the gut microbiome, in combination with lifestyle and environmental factors, influences the early stages of colorectal carcinogenesis. This knowledge will be crucial to develop microbiome-based screening tools for CRC. By evaluating biomarker performance in a screening setting, using samples from the target population, the generalizability of the findings to future screening cohorts is likely to be high. ClinicalTrials.gov Identifier: NCT01538550 .
Sections du résumé
BACKGROUND
BACKGROUND
Colorectal cancer (CRC) screening reduces CRC incidence and mortality. However, current screening methods are either hampered by invasiveness or suboptimal performance, limiting their effectiveness as primary screening methods. To aid in the development of a non-invasive screening test with improved sensitivity and specificity, we have initiated a prospective biomarker study (CRCbiome), nested within a large randomized CRC screening trial in Norway. We aim to develop a microbiome-based classification algorithm to identify advanced colorectal lesions in screening participants testing positive for an immunochemical fecal occult blood test (FIT). We will also examine interactions with host factors, diet, lifestyle and prescription drugs. The prospective nature of the study also enables the analysis of changes in the gut microbiome following the removal of precancerous lesions.
METHODS
METHODS
The CRCbiome study recruits participants enrolled in the Bowel Cancer Screening in Norway (BCSN) study, a randomized trial initiated in 2012 comparing once-only sigmoidoscopy to repeated biennial FIT, where women and men aged 50-74 years at study entry are invited to participate. Since 2017, participants randomized to FIT screening with a positive test result have been invited to join the CRCbiome study. Self-reported diet, lifestyle and demographic data are collected prior to colonoscopy after the positive FIT-test (baseline). Screening data, including colonoscopy findings are obtained from the BCSN database. Fecal samples for gut microbiome analyses are collected both before and 2 and 12 months after colonoscopy. Samples are analyzed using metagenome sequencing, with taxonomy profiles, and gene and pathway content as primary measures. CRCbiome data will also be linked to national registries to obtain information on prescription histories and cancer relevant outcomes occurring during the 10 year follow-up period.
DISCUSSION
CONCLUSIONS
The CRCbiome study will increase our understanding of how the gut microbiome, in combination with lifestyle and environmental factors, influences the early stages of colorectal carcinogenesis. This knowledge will be crucial to develop microbiome-based screening tools for CRC. By evaluating biomarker performance in a screening setting, using samples from the target population, the generalizability of the findings to future screening cohorts is likely to be high.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov Identifier: NCT01538550 .
Identifiants
pubmed: 34407780
doi: 10.1186/s12885-021-08640-8
pii: 10.1186/s12885-021-08640-8
pmc: PMC8371800
doi:
Banques de données
ClinicalTrials.gov
['NCT01538550']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
930Informations de copyright
© 2021. The Author(s).
Références
PLoS One. 2016 May 12;11(5):e0155362
pubmed: 27171425
Clin Epidemiol. 2018 Apr 05;10:381-389
pubmed: 29670403
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Public Health Rev. 2018 Mar 02;39:7
pubmed: 29507820
Clin Cancer Res. 2017 Apr 15;23(8):2061-2070
pubmed: 27697996
Public Health Nutr. 2016 Aug;19(11):2024-32
pubmed: 26780977
Br J Surg. 2008 Aug;95(8):1029-36
pubmed: 18563785
Gut. 2015 Oct;64(10):1637-49
pubmed: 26041752
Nat Commun. 2015 Mar 11;6:6528
pubmed: 25758642
Eur J Clin Nutr. 2003 Feb;57(2):279-84
pubmed: 12571660
JAMA. 2014 Aug 13;312(6):606-15
pubmed: 25117129
Lancet. 1996 Nov 30;348(9040):1467-71
pubmed: 8942774
Gut. 2015 Jan;64(1):121-32
pubmed: 24647008
Nat Med. 2019 Apr;25(4):679-689
pubmed: 30936547
Bioinformatics. 2018 Oct 15;34(20):3600
pubmed: 29788404
Lancet Infect Dis. 2020 Oct;20(10):e251-e260
pubmed: 32768390
Nat Med. 2019 Apr;25(4):667-678
pubmed: 30936548
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):913-933
pubmed: 31648977
Clin Chem. 2018 Sep;64(9):1327-1337
pubmed: 29914865
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
Eur J Cancer Prev. 2018 Jul;27(4):316-322
pubmed: 27824661
Genome Res. 2012 Feb;22(2):299-306
pubmed: 22009989
Cancer Cell. 2018 Jun 11;33(6):954-964
pubmed: 29657127
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Gut. 2015 Aug;64(8):1268-76
pubmed: 25183203
Gastroenterology. 2021 Mar;160(4):1085-1096.e5
pubmed: 33227280
Sci Rep. 2019 Mar 11;9(1):4042
pubmed: 30858400
Lancet. 2017 Apr 1;389(10076):1299-1311
pubmed: 28236467
Ann Intern Med. 2018 Jun 5;168(11):775-782
pubmed: 29710125
Br J Cancer. 2011 May 24;104(11):1779-85
pubmed: 21559011
Nutrients. 2019 Jul 12;11(7):
pubmed: 31336836
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):511-518
pubmed: 31105047
Cancer. 1989 May 1;63(9):1826-30
pubmed: 2702590
BMJ. 2015 Oct 06;351:h4970
pubmed: 26442928
Gastroenterology. 2020 Jan;158(2):418-432
pubmed: 31394083
Int J Epidemiol. 1996 Apr;25(2):235-44
pubmed: 9119547
Am J Epidemiol. 1999 Jul 1;150(1):75-87
pubmed: 10400557
Gut. 2017 Jan;66(1):70-78
pubmed: 26408641
Clin Gastroenterol Hepatol. 2019 Jan;17(2):275-289
pubmed: 30031175
Genome Med. 2016 Apr 06;8(1):37
pubmed: 27056827
Gut. 2019 Sep;68(9):1624-1632
pubmed: 31092590
J Natl Cancer Inst. 2013 Dec 18;105(24):1907-11
pubmed: 24316595
N Engl J Med. 1993 May 13;328(19):1365-71
pubmed: 8474513
BMC Gastroenterol. 2018 Nov 8;18(1):171
pubmed: 30409123
Public Health Nutr. 2002 Jun;5(3):487-96
pubmed: 12003662
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Br J Nutr. 2011 May;105(10):1530-8
pubmed: 21272408
Br J Cancer. 2017 Aug 8;117(4):461-469
pubmed: 28704841
Eur J Cancer. 2009 May;45(7):1218-1231
pubmed: 19091545
Cancer Prev Res (Phila). 2014 Nov;7(11):1112-21
pubmed: 25104642
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):85-94
pubmed: 27672054
Gastroenterology. 2020 Jan;158(2):322-340
pubmed: 31586566
Stat Methods Med Res. 2020 Oct;29(10):2958-2971
pubmed: 32299298
N Engl J Med. 2012 Jun 21;366(25):2345-57
pubmed: 22612596
Int J Surg. 2014 Dec;12(12):1500-24
pubmed: 25046751
Br J Nutr. 2020 Sep 28;124(6):521-530
pubmed: 32238220
Genome Res. 2012 Feb;22(2):292-8
pubmed: 22009990
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet Public Health. 2019 Mar;4(3):e137-e147
pubmed: 30733056
Nutr J. 2010 Sep 15;9:37
pubmed: 20843361
Lancet. 1996 Nov 30;348(9040):1472-7
pubmed: 8942775
Mol Syst Biol. 2014 Nov 28;10:766
pubmed: 25432777
Br J Nutr. 2005 Apr;93(4):519-27
pubmed: 15946415
Nutr J. 2018 Oct 17;17(1):94
pubmed: 30333016
Gastroenterology. 2010 Jun;138(6):2088-100
pubmed: 20420948
J Natl Cancer Inst. 2011 Sep 7;103(17):1310-22
pubmed: 21852264
Nature. 2018 Mar 8;555(7695):210-215
pubmed: 29489753
Endoscopy. 2013 Oct;45(10):842-51
pubmed: 24030244
PLoS Med. 2007 Oct 16;4(10):e297
pubmed: 17941715